Out-of-Pocket Savings Under the Inhaler Price Cap.
作者信息
Mein Stephen A, Kludze Ave K, Feldman William B, Tale Archana P, Stevens Jennifer P, Wadhera Rishi K
机构信息
Section of Health Policy and Equity, Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
出版信息
JAMA Intern Med. 2025 Mar 1;185(3):339-341. doi: 10.1001/jamainternmed.2024.6918.
Abstract
摘要
相似文献
1
Out-of-Pocket Savings Under the Inhaler Price Cap.吸入器价格上限下的自付费用节省情况。
JAMA Intern Med. 2025 Mar 1;185(3):339-341. doi: 10.1001/jamainternmed.2024.6918.
2
Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.医疗保险计划 D 中患者和付款人的专利品牌药与授权仿制药使用激励因素
JAMA Intern Med. 2021 Dec 1;181(12):1605-1611. doi: 10.1001/jamainternmed.2021.5997.
3
Generic script share and the price of brand-name drugs: the role of consumer choice.仿制药共享与品牌药价格：消费者选择的作用。
Int J Health Care Finance Econ. 2009 Sep;9(3):291-316. doi: 10.1007/s10754-008-9052-0. Epub 2009 Jan 8.
4
Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.医生管理药物的仿制药竞争与价格下降的关联，以及预计生物类似药竞争带来的价格下降。
JAMA Netw Open. 2021 Nov 1;4(11):e2133451. doi: 10.1001/jamanetworkopen.2021.33451.
5
The Impact of Sharing Drug Rebates at the Point of Sale on Out-of-Pocket Payments for Enrollees in Employer-Sponsored Insurance.药店药品回扣共享对雇主赞助保险参保者自付费用的影响。
Value Health. 2023 Feb;26(2):226-233. doi: 10.1016/j.jval.2022.08.001. Epub 2022 Sep 14.
6
The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among Individuals With Asthma.美国食品药品监督管理局对氯氟烃的禁令对哮喘患者自付费用及沙丁胺醇吸入器使用情况的影响
JAMA Intern Med. 2015 Jul;175(7):1171-9. doi: 10.1001/jamainternmed.2015.1665.
7
Cost saving of switching to equivalent inhalers and its effect on health outcomes.转换等效吸入器的成本节约及其对健康结果的影响。
Thorax. 2019 Nov;74(11):1078-1086. doi: 10.1136/thoraxjnl-2018-212957. Epub 2019 Aug 5.
8
Long-Term Cost-Effectiveness of Digital Inhaler Adherence Technologies in Difficult-to-Treat Asthma.长期使用数字吸入器依从性技术治疗难治性哮喘的成本效益分析。
J Allergy Clin Immunol Pract. 2023 Oct;11(10):3064-3073.e15. doi: 10.1016/j.jaip.2023.06.051. Epub 2023 Jul 3.
9
Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.品牌药价格变化与患者自付费用的相关性。
JAMA Netw Open. 2021 May 3;4(5):e218816. doi: 10.1001/jamanetworkopen.2021.8816.
10
Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps.美国肿瘤学均等法案下有和无自付费用上限对癌症药物使用和支出的比较。
JAMA Health Forum. 2021 May 28;2(5):e210673. doi: 10.1001/jamahealthforum.2021.0673. eCollection 2021 May.
本文引用的文献
1
US Senate committee investigates asthma inhaler prices.美国参议院委员会对哮喘吸入器价格展开调查。
Lancet Respir Med. 2024 Apr;12(4):270. doi: 10.1016/S2213-2600(24)00012-2. Epub 2024 Jan 23.
2
Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986-2020.哮喘和 COPD 吸入器的专利和监管专有权，1986-2020 年。
Health Aff (Millwood). 2022 Jun;41(6):787-796. doi: 10.1377/hlthaff.2021.01874. Epub 2022 May 17.
3
Medication adherence and the risk of severe asthma exacerbations: a systematic review.药物依从性与严重哮喘恶化风险：系统评价。
Eur Respir J. 2015 Feb;45(2):396-407. doi: 10.1183/09031936.00075614. Epub 2014 Oct 16.
4
Clinical and economic impact of non-adherence in COPD: a systematic review.慢性阻塞性肺疾病（COPD）中不依从治疗的临床和经济影响：一项系统综述
Respir Med. 2014 Jan;108(1):103-13. doi: 10.1016/j.rmed.2013.08.044. Epub 2013 Sep 11.
5
Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease.老年人慢性肺部疾病患者的吸入器成本和药物不依从性。
Chest. 2010 Sep;138(3):614-20. doi: 10.1378/chest.09-3031. Epub 2010 Apr 23.
Zotero 插件